Plus, news about Bioinvent, Alpha Cognition, Neumirna Therapeutics and Cassava Sciences: Sana Biotechnology finds life with new type 1 diabetes cell therapy data: The once
A new startup aiming to tackle rare diseases de-stealthed Wednesday morning with a CEO experienced in the space. Alesta Therapeutics took the wraps off its
Chugai, a Japanese pharma owned by Roche, is partnering with a small Swiss biotech to work on next-generation antibody-drug conjugates that deliver multiple cytotoxic molecules
A new startup has emerged with $200 million and access to multiple preclinical drug candidates from neuroscience drugmaker Denali Therapeutics. On Wednesday morning, South San
A Canadian biotech creating bioprinted tissue therapeutics for type 1 diabetes, obesity and other endocrine and metabolic disorders has raised $115 million in a Series
Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, believing its software will help prevent
Women are less likely than men to get a needed lung transplant and spend an average of 6 weeks longer waiting for one, but they
A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, albeit with a high incidence of hematologic toxicity
The increasing involvement of private equity in the healthcare system “potentially pose[s] a threat to the nation’s healthcare infrastructure, particularly in underserved and rural areas,”
Clearance of driver mutations at day 30 after transplantation was associated with a reduced risk of relapse and better survival among patients with myelofibrosis, a